Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | JAK2 R867Q |
Gene Variant Detail | |
Relevant Treatment Approaches | JAK Inhibitor (Pan) JAK Inhibitor (Pan) - ATP competitive JAK2 Inhibitor JAK2 Inhibitor - ATP competitive |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
JAK2 R867Q | hematologic cancer | decreased response | JAK2 Inhibitor - ATP competitive | Fedratinib | Preclinical - Cell culture | Actionable | In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Inrebic (fedratinib) in culture (PMID: 24398328). | 24398328 |
JAK2 R867Q | hematologic cancer | decreased response | JAK2 Inhibitor - ATP competitive | Ruxolitinib | Preclinical | Actionable | In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Jakafi (ruxolitinib) in culture (PMID: 24398328). | 24398328 |
JAK2 R867Q | hematologic cancer | decreased response | JAK2 Inhibitor - ATP competitive | AZ960 | Preclinical | Actionable | In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AZ960 in culture (PMID: 24398328). | 24398328 |
JAK2 R867Q | hematologic cancer | decreased response | JAK2 Inhibitor - ATP competitive | Momelotinib | Preclinical | Actionable | In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Momelotinib (CYT387) in culture (PMID: 24398328). | 24398328 |
JAK2 R867Q | hematologic cancer | decreased response | Luminespib | Preclinical | Actionable | In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Luminespib (AUY922) in culture (PMID: 24398328). | 24398328 |